Germline HLA and KIR Variation and Disease Control After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer: Exposure Definition Shapes the Signal
Immune checkpoint inhibitors (ICIs) benefit only a minority of patients with advanced non-small cell lung cancer (NSCLC). Whether germline human leukocyte antigen (HLA) or killer cell immunoglobulin-like receptor (KIR) variation identifies them is unclear, partly because studies define HLA exposures differently. We ask...